Unknown PHASE2 INTERVENTIONAL 2-arm NCT00786331

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC).

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Conditions Advanced Non-Small Cell Lung Cancer

Interventions Pemetrexed Pemetrexed plus carboplatin

Updated 6 times since 2017 Last updated: Jul 31, 2009 Started: Jul 31, 2007 Primary completion: Jul 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Non-Small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Gruppo Oncologico Italiano di Ricerca Clinica and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gruppo Oncologico Italiano di Ricerca Clinica

Data source: Gruppo Oncologico Italiano di Ricerca Clinica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Bergamo, Italy , Cremona, Italy , Cuneo, Italy , Fano, PU, Italy , Florence, Italy , Genova, Italy , Lido Di Camaiore, LU, Italy , Livorno, Italy , Meldola, FC, Italy and 11 more locations